News | September 03, 2007

Study Shows Significant Reduction in Blood Clots and Reintervention With Cypher Sirolimus-eluting Coronary Stent

September 4, 2007 - Analysis of clinical trials showed the Cypher Sirolimus-eluting coronary stent was associated with significantly lower risks of blood clots and the need for reintervention, compared to the Taxus stent out to 30 months after an angioplasty procedure.
This meta-analysis of 16 randomized clinical trials and 8,695 patients, the largest analysis of its kind to date, is posted on the Journal of the American College of Cardiology Website and is expected in print later in the year.
"Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents," said professor Albert Schomig, M.D., from Deutsches Herzzentrum, Technische Universitat in Munich, Germany, one of the authors of the study. "In this meta-analysis of randomized controlled trials, the Cypher stent was associated with a significant reduction in the risks of stent thrombosis and reintervention compared to the Taxus stent. This reinforces the notion that there are marked differences between the Cypher stent and the Taxus stent and that the safety of these drug-eluting stents must be assessed separately."
Schomig added, "We find these data compelling because they are consistent with other documented meta-analyses and reflect data from all of the randomized clinical trials directly comparing these drug-eluting stents."
He said the primary safety endpoint of the meta-analysis was protocol-defined stent thrombosis, while the secondary safety endpoints were death and heart attack. The primary efficacy endpoint was the need for reintervention (target lesion revacularization or TLR).
According to this comprehensive analysis of all head-to-head clinical studies between the Cypher stent and the Taxus stent, a blood clot (stent thrombosis) is 34 percent less likely to form in patients implanted with the Cypher stent than in patients who receive the Taxus stent.
While the overall risk of death was not significantly different between the two drug-eluting stents, the authors of the meta-analysis identified a trend toward a lower risk of heart attack with the Cypher stent versus the Taxus, especially after the first year of follow-up.
"This meta-analysis substantially enriches the large body of evidence that interventional cardiologists have at their disposal to make the right choice for their patients," said David E. Kandzari, MD, FACC, FSCAI, chief medical officer, Cordis Corporation.
The meta-analysis comprised studies of simple cases, studies that included all types of patients and studies that focused on specific and complex patient populations, such as patients with diabetes, patients treated for disease in long lesions or small vessels, patients presenting with a heart attack and patients being treated for repeat disease in a previously placed bare-metal stent, some of which are not within the approved labeling for the products.

For more information: www.cordis.com

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init